Encorafenib/Cetuximab/Binimetinib Triplet Safe and Effective in BRAF V600E–Mutant mCRC
May 16th 2023Treatment with encorafenib in combination with cetuximab and binimetinib was active with a manageable safety profile in the first-line setting for patients with BRAF V600E–mutated metastatic colorectal cancer.
Aumolertinib Plus SRT Achieves Intracranial Responses in Oligometastatic EGFR+ NSCLC
May 10th 2023Prospective phase 2 data demonstrated that aumolertinib, followed by salvage stereotactic radiation therapy, elicited responses in patients with intracranial oligometastatic EGFR-mutant non–small cell lung cancer.
Extended Anastrozole Therapy Improves DFS in Postmenopausal Patients With HR+ Breast Cancer
May 9th 2023Extending anastrozole treatment to 10 years in postmenopausal women with hormone receptor–positive breast cancer who have no evidence of disease after 5 years of standard-of-care treatments.